Grufity logoGrufity logo

Incyte Corp Stock Research

INCY

71.86USD-0.40(-0.55%)Market Closed

Market Summary

USD71.86-0.40
Market Closed
-0.55%

INCY Alerts

INCY Stock Price

INCY RSI Chart

INCY Valuation

Market Cap

16.0B

Price/Earnings (Trailing)

46.99

Price/Sales (Trailing)

4.72

EV/EBITDA

21.77

Price/Free Cashflow

16.5

INCY Price/Sales (Trailing)

INCY Profitability

Operating Margin

93.90%

EBT Margin

15.59%

Return on Equity

7.8%

Return on Assets

5.83%

Free Cashflow Yield

6.06%

INCY Fundamentals

INCY Revenue

Revenue (TTM)

3.4B

Revenue Y/Y

7.4%

Revenue Q/Q

12.56%

INCY Earnings

Earnings (TTM)

340.7M

Earnings Y/Y

-94.95%

Earnings Q/Q

-74.76%

Price Action

52 Week Range

65.0786.29
(Low)(High)

Last 7 days

-2.8%

Last 30 days

-8.5%

Last 90 days

-11.7%

Trailing 12 Months

-6.8%

INCY Financial Health

Current Ratio

3.54

INCY Investor Care

Shares Dilution (1Y)

0.75%

Diluted EPS (TTM)

1.52

Peers (Alternatives to Incyte)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
98.0B
27.3B
-7.18% 37.83%
21.33
3.59
-0.09% -26.23%
57.1B
19.3B
-7.28% -16.95%
6.83
2.97
4.29% -31.47%
16.0B
3.4B
-8.45% -6.80%
46.99
4.72
13.67% -64.09%
11.8B
2.1B
7.92% 0.14%
-18.87
5.64
17.95% -4.68%
MID-CAP
5.9B
1.6B
4.36% -14.51%
32.36
3.66
12.27% -21.11%
3.5B
5.4B
-8.08% -56.83%
13.04
0.64
3.46% 13.48%
3.1B
108.5M
-20.63% -31.77%
-9.51
28.59
122.90% -12.19%
2.5B
278.3M
-25.09% -47.78%
-16.35
9.08
92.72% 15.56%
SMALL-CAP
664.8M
-
-14.80% -31.35%
-13.28
291.16
-34.21% -22.31%
499.9M
2.0B
-38.13% -92.75%
-0.76
0.25
72.89% 62.27%
193.6M
80.7M
-28.46% -55.92%
6.84
4.15
13.30% 130.72%
143.9M
60.3M
-71.28% -88.95%
-0.29
2.39
17.51% -38.93%
16.2M
-
-31.53% -19.40%
-0.25
-
- -67.11%
14.8M
-
-16.13% -29.35%
-2.15
-
- 20.96%

Financials for Incyte

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue1.9%3,3953,3313,3203,1152,986
  S&GA Expenses4.9%1,002956880795740
  R&D Expenses1.8%1,5861,5571,5081,5051,458
Costs and Expenses3.9%2,8152,7112,6032,5112,400
EBITDA-5.7%600636694634-
EBITDA Margin-7.5%0.18*0.19*0.21*0.20*-
Earnings Before Taxes-6.9%529569629572570
EBT Margin-8.7%0.16*0.17*0.19*0.18*-
Interest Expenses-3.1%3.003.003.002.002.00
Net Income-61.1%341876945933949
Net Income Margin-61.8%0.10*0.26*0.28*0.30*-
Free Cahsflow21.0%970802760759-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets6.0%5,8415,5105,3195,0544,933
  Current Assets7.1%4,0933,8213,6263,2883,119
    Cash Equivalents9.7%2,9512,6912,4352,2572,057
  Inventory-8.4%42.0046.0055.0036.0028.00
  Net PPE3.3%739716721729724
  Goodwill0%156156156156156
Liabilities14.6%1,4711,2841,2341,1911,163
  Current Liabilities14.9%1,1571,007927886854
Shareholder's Equity3.4%4,3704,2274,0853,8633,770
  Retained Earnings6.1%-437-465-578-739-777
  Additional Paid-In Capital1.5%4,7924,7214,6894,6264,567
Accumulated Depreciation5.3%202192186176-
Shares Outstanding0.1%223222222221221
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations21.0%970802760759749
  Share Based Compensation2.4%188184181179183
Cashflow From Investing36.5%-78.54-123-128-164-207
Cashflow From Financing-107.4%-0.7911.006.00-6.566.00

Risks for INCY

What is the probability of a big loss on INCY?

76.2%


Probability that Incyte stock will be more than 20% underwater in next one year

24.2%


Probability that Incyte stock will be more than 30% underwater in next one year.

12.3%


Probability that Incyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INCY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Incyte was unfortunately bought at previous high price.

Drawdowns

Returns for INCY

Cumulative Returns on INCY

12.5%


10-Year Cumulative Returns

0.4%


7-Year Cumulative Returns

-2.9%


5-Year Cumulative Returns

4.4%


3-Year Cumulative Returns

What are the long-term rolling returns for INCY?

FIve years rolling returns for Incyte.

Annualized Returns

Which funds bought or sold INCY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-0.28
42,835
259,835
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-40.84
-5,398,430
13,416,600
0.01%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
2,253
13,253
-%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
unchanged
-
155,632
911,632
0.06%
2023-03-06
Rockefeller Capital Management L.P.
added
71.5
1,115,000
2,159,000
0.01%
2023-02-28
Voya Investment Management LLC
added
1.74
2,233,340
12,103,300
0.02%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
365
1,365
-%
2023-02-24
National Pension Service
reduced
-4.2
3,226,530
24,017,000
0.05%
2023-02-24
NATIXIS
reduced
-89.37
-9,121,060
1,340,940
0.01%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
232,000
1,364,000
0.01%

1–10 of 47

Latest Funds Activity

Are funds buying INCY calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own INCY
No. of Funds

Incyte News

BioWorld Online

US FDA approves Incyte's PD-1 inhibitor Zynyz for Merkel cell ....

BioWorld Online,
114 minutes ago

Marketscreener.com

Schedule 13G FIlings of Incyte

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 15, 2023
baker bros. advisors lp
16.3%
36,280,967
SC 13D/A
Feb 14, 2023
dodge & cox
8.7%
19,362,935
SC 13G/A
Feb 09, 2023
vanguard group inc
9.68%
21,533,818
SC 13G/A
Jan 25, 2023
blackrock inc.
8.9%
19,836,617
SC 13G/A
Mar 10, 2022
baker bros. advisors lp
16.4%
36,269,307
SC 13D/A
Feb 14, 2022
baker bros. advisors lp
15.7%
34,851,571
SC 13D/A
Feb 14, 2022
price t rowe associates inc /md/
3.2%
7,271,688
SC 13G/A
Feb 14, 2022
dodge & cox
7.5%
16,657,586
SC 13G
Feb 10, 2022
vanguard group inc
9.48%
20,944,759
SC 13G/A
Feb 04, 2022
wellington management group llp
4.08%
9,008,491
SC 13G/A

INCY Fair Value

Incyte fair value in different scenarios

The table shows the Fair Value estimates for Incyte for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

48.22

-32.90%

63.57

-11.54%

84.15

17.10%

115.61

60.88%

150.79

109.84%
Current Inflation

44.44

-38.16%

57.60

-19.84%

74.84

4.15%

101.28

40.94%

130.89

82.15%
Very High Inflation

39.77

-44.66%

50.39

-29.88%

63.83

-11.17%

84.62

17.76%

107.94

50.21%

Historical Incyte Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Incyte

View All Filings
Date Filed Form Type Document
Mar 15, 2023
4
Insider Trading
Mar 15, 2023
SC 13D/A
13D - Major Acquisition
Feb 21, 2023
4
Insider Trading
Feb 15, 2023
4
Insider Trading
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 08, 2023
SC 13G/A
Major Ownership Report
Feb 07, 2023
8-K
Current Report
Feb 07, 2023
10-K
Annual Report
Feb 02, 2023
4
Insider Trading

Latest Insider Trading transactions for INCY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
BAKER BROS. ADVISORS LP
acquired
909,600
22.74
40,000
-
2023-02-16
Dhanak Dashyant
acquired
241,596
65.42
3,693
evp & chief scientific officer
2023-02-13
Stamoulis Christiana
sold (taxes)
-94,414
80.08
-1,179
evp & chief financial officer
2023-01-31
Pasquale Maria E
acquired
59,973
74.78
802
evp & general counsel
2023-01-31
Pasquale Maria E
sold
-67,416
84.06
-802
evp & general counsel
2023-01-30
Pasquale Maria E
sold
-5,086,570
84.7422
-60,024
evp & general counsel
2023-01-30
Pasquale Maria E
acquired
4,405,220
73.391
60,024
evp & general counsel
2023-01-26
Iyengar Vijay K
sold
-595,000
85.00
-7,000
evp, gmapps
2023-01-26
Iyengar Vijay K
acquired
480,340
68.62
7,000
evp, gmapps
2023-01-26
Dhanak Dashyant
sold
-205,615
85.00
-2,419
evp & chief scientific officer

1–10 of 50

Herve Hoppenot
2090
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 823,303$ 812,987$ 2,467,935$ 2,123,414
Costs and expenses:    
Cost of product revenues (including definite-lived intangible amortization)54,58439,869147,834107,117
Research and development384,007334,9451,084,576985,352
Selling, general and administrative266,460190,704729,321513,358
(Gain) loss on change in fair value of acquisition-related contingent consideration(21,893)2,910(12,198)13,068
Collaboration loss sharing1,7699,1499,05529,476
Total costs and expenses684,927577,5771,958,5881,648,371
Income from operations138,376235,410509,347475,043
Other income (expense), net11,5131,94813,2954,931
Interest expense(641)(439)(1,999)(1,156)
Unrealized loss on long term investments(660)(27,450)(72,142)(28,394)
Income before provision for income taxes148,588209,469448,501450,424
Provision for income taxes35,81327,730136,30265,694
Net income$ 112,775$ 181,739$ 312,199$ 384,730
Net income per share:    
Basic (in USD per share)$ 0.51$ 0.82$ 1.41$ 1.75
Diluted (in USD per share)$ 0.50$ 0.82$ 1.40$ 1.73
Shares used in computing net income per share:    
Basic (in shares)222,415220,845221,801220,243
Diluted (in shares)224,175222,248223,626222,113
Product revenues, net    
Revenues:    
Total revenues$ 713,010$ 594,013$ 1,982,682$ 1,673,974
Product royalty revenues    
Revenues:    
Total revenues110,293183,974350,253404,440
Milestone and contract revenues    
Revenues:    
Total revenues$ 0$ 35,000$ 135,000$ 45,000

INCY Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 2,690,622,000$ 2,057,440,000
Marketable securities—available-for-sale (amortized cost $292,941 and $291,871 as of September 30, 2022 and December 31, 2021, respectively; allowance for credit losses $0 as of September 30, 2022 and December 31, 2021)286,500,000290,752,000
Accounts receivable618,188,000616,300,000
Inventory45,869,00027,904,000
Prepaid expenses and other current assets179,932,000126,278,000
Total current assets3,821,111,0003,118,674,000
Restricted cash and investments1,601,0001,720,000
Long-Term Investments149,124,000221,266,000
Inventory55,264,00029,034,000
Property and equipment, net715,733,000723,920,000
Finance lease right-of-use assets, net26,679,00027,548,000
Other intangible assets, net134,603,000150,755,000
Goodwill155,593,000155,593,000
Deferred income tax asset426,840,000467,538,000
Other assets, net23,666,00037,304,000
Total assets5,510,214,0004,933,352,000
Current liabilities:  
Accounts payable163,175,000172,110,000
Accrued compensation106,309,000108,962,000
Accrued and other current liabilities699,814,000533,595,000
Finance lease liabilities3,112,0002,635,000
Acquisition-related contingent consideration34,186,00037,006,000
Total current liabilities1,006,596,000854,308,000
Acquisition-related contingent consideration171,814,000206,994,000
Finance lease liabilities30,476,00031,632,000
Other liabilities74,677,00070,414,000
Total liabilities1,283,563,0001,163,348,000
Commitments and contingencies (Note 14)
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding00
Common stock, $0.001 par value; 400,000,000 shares authorized; 222,454,839 and 221,084,433 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively222,000221,000
Additional paid-in capital4,721,166,0004,567,111,000
Accumulated other comprehensive loss(29,062,000)(19,454,000)
Accumulated deficit(465,675,000)(777,874,000)
Total stockholders’ equity4,226,651,0003,770,004,000
Total liabilities and stockholders’ equity$ 5,510,214,000$ 4,933,352,000